SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Revenue for the quarter ended  December 2023 of Rs. 50737.50 millions grew by 9.21 % from Rs. 46457.50 millions.A comparatively good net profit growth of 48.20% to Rs. 7213.10 millions was reported for the quarter ended December 2023 compared to Rs. 4867.30 millions of previous same quarter.Operating profit surged to 14358.00 millions from the corresponding previous quarter of 10674.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 50737.50 46457.50 9.21 146360.30 148639.20 -1.53 208121.40 155859.80 33.53
Other Income 2284.80 746.30 206.15 5079.50 2925.50 73.63 3292.90 11968.80 -72.49
PBIDT 14358.00 10674.10 34.51 40409.60 42709.40 -5.38 67518.90 38654.40 74.67
Interest 2149.20 1308.90 64.20 5664.90 3107.30 82.31 4721.80 3881.00 21.66
PBDT 11510.70 9365.20 22.91 32554.50 39602.10 -17.80 33419.20 16568.10 101.71
Depreciation 3996.00 4304.40 -7.16 12075.80 11888.90 1.57 16008.70 13499.50 18.59
PBT 7514.70 5060.80 48.49 20478.70 27713.20 -26.10 17410.50 3068.60 467.38
TAX 301.60 193.50 55.87 572.90 597.80 -4.17 503.30 4068.50 -87.63
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 7213.10 4867.30 48.20 19905.80 27115.40 -26.59 16907.20 -999.90 -1790.89
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 28.30 22.98 23.17 27.61 28.73 -3.91 32.44 24.80 30.81

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×